Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infection.
СтатьяResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsou Pei-Suen, Ali Ramadan A, Lu Chenyang, Sule Gautam, Carmona-Rivera Carmelo, Lucotti Serena, Ikari Yuzo, Wu Qi, Campbell Phillip L, Gurrea-Rubio Mikel, Maeda Kohei, Fox Sharon E, Brodie William D, Mattichak Megan N, Foster Caroline, Tambralli Ajay, Yalavarthi Srilakshmi, Amin M Asif, Kmetova Katarina, Fonseca Bruna Mazetto, Chong Emily, Zuo Yu, Maile Michael D, Imberti Luisa, Caruso Arnaldo, Caccuri Francesca, Quaresima Virginia, Sottini Alessandra, Kuhns Douglas B, Fink Danielle, Castagnoli Riccardo, Delmonte Ottavia M, Kenney Heather, Zhang Yu, Magliocco Mary, Su Helen, Notarangelo Luigi, Zemans Rachel L, Mao-Draayer Yang, Matei Irina R, Salvatore Mirella, Lyden David, Kanthi Yogendra, Kaplan Mariana J, Knight Jason S, Fox David A
Аннотация
The soluble variant of the ectopeptidase CD13 (sCD13), released from the cell surface by matrix metalloproteinase 14 (MMP14), is a potent pro-inflammatory mediator, displaying chemotactic, angiogenic, and arthritogenic properties through bradykinin receptor B1 (B1R). We revealed a link between sCD13 and amplified neutrophil-mediated inflammatory responses in SARS-CoV-2 infection. sCD13 was markedly elevated in patients with COVID-19 and correlated with disease severity and variants, ethnicity, inflammation markers, and neutrophil extracellular trap formation (NETosis). Neutrophils treated with sCD13 showed heightened NETosis and chemotaxis, which were inhibited by sCD13 receptor blockade. Meanwhile sCD13 did not induce platelet aggregation. Single-cell analysis of COVID-19 lungs revealed coexpression of CD13 and MMP14 by various cell types, and higher CD13 expression compared with controls. Neutrophils with high CD13 mRNA were enriched for genes associated with immaturity, though CD13 protein expression was lower. Histological examination of COVID-19 lungs revealed CD13-positive leukocytes trapped in vessels with fibrin thrombi. Flow cytometry verified the presence of B1R and a second sCD13 receptor, protease-activated receptor 4, on monocytes and neutrophils. These findings identify sCD13 as a potential instigator of COVID-19-associated NETosis, potentiating vascular stress and thromboembolic complications. The potent pro-inflammatory effects of sCD13 may contribute to severe COVID-19, suggesting that sCD13 and its receptors might be therapeutic targets.